HACKENSACK, N.J., Sept. 8, 2015 /PRNewswire/ -- Champions Oncology
(CSBR), a company engaged in the development of advanced technology
solutions and services to personalize the development and use of
oncology drugs, today announced it will report its financial and
operational results for the first quarter ended July 31, 2015, on Thursday, September 10, 2015, after the market
close.
The company will host a conference call to discuss the results
that day at 4:00 p.m. EDT
(1:00 p.m. PDT). To participate in
the call, please call 800-875-3456 (domestic), 800-648-0973
(Canadian Toll Free) or 302-607-2001 (international) ten minutes
ahead of the call and give the verbal passcode "Champions
Oncology."
An MP3 recoding of the call will be available on the Investor
tab of the company's website within 72 hours.
About Champions Oncology
Champions Oncology, Inc. is engaged in the development of
advanced technology solutions and services to personalize the
development and use of oncology drugs. The company's technology
platform is a novel approach to personalizing cancer care based
upon the implantation of primary human tumors in immune-deficient
mice to create Champions TumorGraft® models that preserve the
biological characteristics of the original human tumor in order to
determine the efficacy of a treatment regimen. The company uses
this technology in conjunction with related services to offer
solutions for two customer groups: Personalized Oncology Solutions,
in which results help guide the development of personalized
treatment plans, and Translational Oncology Solutions, in which
pharmaceutical and biotechnology companies seeking personalized
approaches to drug development can lower the cost and increase the
speed of developing new drugs. For more information, please
visit www.championsoncology.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/champions-oncology-to-announce-first-quarter-financial-results-on-thursday-september-10-2015-300139020.html
SOURCE Champions Oncology, Inc.